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The PHQ-2 as a Screening Tool for Clinical Depression 
in a Primary Eye-Care Clinic
ABSTRACT
Purpose: Screening tests for clinical depression, a highly prevalent and 
often disabling condition, have not been investigated in primary-care eye 
settings. The purpose of the present study was to determine the percent of 
patients in an urban primary-care eye clinic who fail the PHQ-2 screening 
tool. The PHQ-2 is an ultra-short screener consisting of 2 items regarding 
mood and anhedonia. 
Methods: The two-question PHQ-2 was administered (as part of a larger 
questionnaire that included data on gender, age, and ethnicity) to patients 
seated in the Primary Care Clinic of the SUNY College of Optometry [Uni-
versity Eye Center] in Manhattan, NY. A total of 739 surveys were complet-
ed over a two-month period, with a completion rate of 69%. All surveys 
were completed anonymously, and unfinished surveys were not included 
in the final data set. 
Results: The demographics collected in this study mirror those of the pop-
ulation that this clinic serves; overall very diverse, with good representa-
tion from each age group. Thirteen percent of the sample received a score 
of 3 or higher, the standard cutoff score for failure of the PHQ-2. 
Conclusions: The failure rate on the PHQ-2 in a primary eye-care, urban 
population approaches that found in general medical practice, suggesting 
similar rates of clinical depression. Thus, the PHQ-2 may be a beneficial 
tool for screening for depression, however, it is important to follow-up with 
a referral to a mental health specialist. 
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The lifetime prevalence of major depression may be as high as 16%.1 About 5 -10% of patients in primary care settings 
suffer from major depression, while dysthymia, a chronic low-grade depression, affects 2 to 4% of this population.2 These 
conditions result in significant suffering, morbidity and mortality.3,4 Major depression is a leading cause of disability in 
adults, and is expected to soon rank second only to heart disease worldwide.5,6 The only chronic condition that is more 
prevalent in general medical practice is hypertension.7,8 Depressed patients are more likely to attempt or commit suicide.9
Despite the increasing availability of effective treatments,10-14 both medical and psychological, it is estimated that as few 
as 22% of patients with major depressive disorder receive appropriate care.1 Since symptoms may not be apparent to the 
practitioner during routine primary-care medical encounters, there is great interest in developing screening surveys that 
can be employed in such settings to effectively screen for this disease.4,15-17 To encourage the use of these screening tools in 
primary-care medical practice, where time constraints make efficiency a major consideration, the trend has been toward 
the use of shorter instruments, including ultra-short (one-, two-, three- and four-item) surveys.3,4,16,18-32
The most widely studied of the ultra-short screening surveys, the PHQ-2, consists of the first two items of the longer 
nine-item Patient Health Questionnaire (PHQ-9).16,17 The two questions, which are based on symptoms specified by 
the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), concern mood and anhedonia 
(Table 1).33 The PHQ-2 has been studied in various clinical populations, including primary care, geriatric, cardiol-
ogy, obstetrics-gynecology and general medical.4,16,18-27,29-32 The most detailed studies with primary-care populations 
found sensitivities ranging from 79 – 83% and specificity ranging from 86 – 92%.16,23,25 These findings point to its 
possible utility as a tool for screening patients seeking primary care services.25
Table 1: Patient Health Questionnaire-2 (PHQ-2)
Over the last 2 weeks, how often have you been 
bothered by any of the following problems? Not at all Several days




a. Little interest or pleasure in doing things q q q q
b. Feeling down, depressed, or hopeless q q q q
PHQ-2 Copyright© 1999 Pfizer Inc. All rights reserved. Reproduced with permission.
Few data are available on the prevalence of clinical depression among patients seeking eye care. In a survey of op-
tometric practices, Soroka et al. determined that only 0.41% of optometric patients had a diagnosis of depression, 
considerably below what would be expected based on the condition’s prevalence in the general population and 
primary-care medical settings.34,35 This value, which is based on case histories, does not take into account undiag-
nosed patients or those unwilling to reveal a diagnosis of depression. 
The current study was undertaken to determine the failure rate for the PHQ-2 when administered in a large urban 
primary-care eye clinic. While the results obtained with a screening device do not indicate the prevalence of clinical 
depression, they provide a basis for comparison with the findings in other primary-care settings. 
METHODS
Subjects and Procedure
Patients seated in the waiting area of the Primary Care Clinic of the SUNY, College of Optometry, University Eye 
Center (UEC) were individually asked by one of the investigators if they would be interested in completing a short 
survey. The UEC, which is located in midtown Manhattan, provides eye-care services to a diverse urban population.
If the patient agreed, he/she was given the survey and a consent statement along with an envelope in which to place 
the survey once it was completed. Both the top and bottom of the one-page survey displayed the statement “DO NOT 
WRITE OR SIGN YOUR NAME ON THIS FORM.” A statement asking the subject to read the accompanying consent 
prior to completing the survey was also printed on the survey form, as were statements that “answers to the questions 
on the survey are anonymous” and “no one, including the researchers, will know how you answered the survey ques-
tions.” The envelopes containing the surveys were subsequently collected by the investigator, who placed them in a 
bag in the patient’s presence. Minimum age for participation in the study was 18 years. The experimental protocol was 
approved by the SUNY State College of Optometry Institutional Review Board.
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A total of 739 surveys were completed over a period of about two months. Based on the final 797 potential subjects 
who were approached, the survey completion rate was 69%. About 16% refused to take the survey, and 2% of the 
returned surveys were incomplete. The remaining potential subjects could not complete the survey due to language 
barriers (6%), disability (1%), because they were called in for their exam (3%) or because they had been dilated and 
were unable to clearly see the survey items (3%).
Survey Instrument 
The survey consisted of 10 items, with the first two from the PHQ-2 (Table 1). Included in the remaining items were 
questions related to demographics (age, gender and ethnicity). A Likert scale was used for the PHQ-2. Data for each 
completed survey were entered into an SPSS database for analysis.
RESULTS
Table 2 summarizes the demographic characteristics of our sample, which appear to be representative of the popu-
lation served by the clinic. Results of the PHQ-2 are given in Table 3, which shows that cutoff values of 2, 3, and 4 
gave failure rates of 0.29, 0.13 and 0.07 respectively. A score of 3 or higher is normally considered a failing score.23
Table 2: Sample demographics
Demographic Sample (n, %)
Age (y)
     18-30 198 (26.8%)
     31-45 156 (21.1%)
     46-60 230 (31.1%)
     61-75 132 (17.9%)
     76 or older 23 (3.1%)
Gender 
     Male 264 (35.7%)
     Female 474 (64.1%)
Race/Ethnicity
     Asian 69 (9.3%)
     Black 227 (30.7%)
     Caucasian 278 (37.6%)
     Hispanic 117 (15.8%)
     Native American 5 (0.7%)
     Mixed 43 (5.8%)




Frequency Percent Cumulative Percent
6 12 1.6 1.6
5 8 1.1 2.7
4 34 4.6 7.3
3* 40 5.4 12.7
2 118 16.0 28.7
1 89 12.0 40.7
0 438 59.3 100.0
*Standard cut-off point
DISCUSSION
A limitation of the current study is that the actual prevalence of clinical depression in the sample was not deter-
mined. To do so would have required a structured diagnostic clinical interview of all subjects. The most frequently 
used of these is the Structured Clinical Interview for DSM-IV (SCID), a lengthy and tedious process that was nei-
ther feasible nor appropriate with our sample.36 The PHQ-2 failure rate, however, has been determined in patient 
samples with a known prevalence of clinical depression. These data may be used to infer the prevalence of clinical 
depression when the PHQ-2 failure rate is known.23,25
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A cutoff score of 3, the standard cutoff score for the PHQ-2, resulted in a 13% failure rate in our sample taken from 
an urban primary-care eye clinic.23,25 In a sample derived from primary-care medical and obstetrics-gynecology 
clinics that had a 7% prevalence of depression as determined with structured interviews, Kroenke et al. found that 
15.2% scored 3 or higher on the PHQ-2.23 The PHQ-2 failure rates for the primary-care eye sample in the current 
study and medical/obstetrics-gynecological samples in previous studies are comparable, suggesting a similar preva-
lence of clinical depression.
The results reported herein point to a considerably higher prevalence of depression amongst optometric patients 
than might be suspected based on a survey of optometric practices that found 0.41% of patients with this condi-
tion.34,35 This latter figure reflects reliance on case history to determine if depression is present. The 13% PHQ-2 
failure rate found in our sample is similar to that in primary-care medical practices, where 7% of the patients were 
diagnosed with depression, leading one to suspect that the prevalence in primary-care optometric practices, par-
ticularly urban practices with demographics similar to ours, approaches 7%.23
The practical application of these findings to eye-care is complex. Meta-analysis of two-and three-question screen-
ing instruments revealed a negative predictive value as low as 93%, indicating that up to 7% of subjects who pass 
the test are clinically depressed.28 Of greater practical import is that, despite its relatively high specificity, most of 
the patients who fail the PHQ-2 will not meet the diagnostic criteria for major depression or dysthymia.23 Two- and 
three- question screeners have a positive predictive value of about 0.4, meaning that only four of ten patients who 
fail the screener are clinically depressed.23,28
If the PHQ-2 was used in isolation to screen to depression, without follow-up, it would result in an unjustifi-
ably high over-referral rate. For this reason, it has been recommended that ultra-short screening instruments 
should only be administered when failing scores can be followed-up with a diagnostic interview or longer survey 
of higher specificity, such as the PHQ-9, which has additional items specific to the DSM-IV diagnostic criteria, 
including items related to suicidal ideations.23,28 Patients who fail the more comprehensive screening can then 
be referred for a mental health evaluation. This two-stage screening may be practicable in eye clinics situated in 
multidisciplinary settings. 
In summary, results with the PHQ-2 screening instrument suggest that the prevalence of clinical depression in the 
primary-care patient population of an urban eye-care clinic may approach that of medical primary-care settings. 
The availability of appropriate follow-up, however, is of upmost importance when using this screening tool in eye-
care practices. l
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